Partner Presentation Candiolo Cancer Institute, FPO – IRCCS

Dec 19, 2023 | Newsletter #6

Partner presentation: Candiolo Cancer Institute, FPO – IRCCS

The Candiolo Cancer Institute mission is to give significant contribution to fight cancer, by understanding the basics and providing state-of-the-art diagnostic and therapeutic services. The Institute works in synergy with the University of Torino Medical School and the interface between molecular biology and medicine is at its core. The interaction between experimental and clinical expertise allows constant transfer of innovative care models into the clinic. The Image and Data Processing (IDP)-Lab, embedded in the Imaging Unit of the Candiolo Cancer Institute, has been actively pursuing research on prostate MRI and computer aided detection (CAD) systems since the last  decade, using artificial intelligence (AI) driven technologies. The Laboratory is directed by Prof. Regge, who is a pioneer in the field of in-vivo imaging biomarkers and is internationally recognized for his contributions to CT colonography and prostate MRI. The research team at the Candiolo Cancer Institute is composed by a multidisciplinary, multi-investigator group, involving researchers from different fields: medical imaging, biomedical engineer, computer science, radiology, urology and pathology. The team has interdisciplinary competences ranging from biology and experimental work to biostatistics and data analysis.

The Candiolo Cancer Institute has participated to set the legal and ethical framework of retrospective and prospective data collections (WP2), is actively involved in the dissemination and communication activities (WP3), in developing the master (WP5), vendor specific and vendor neutral (WP6) models. Since the IDP-Lab has a large experience in developing and validating AI models for the detection and characterization of prostate cancer to predict the risk of cancer progression, the group is task  leader in the development and validation of models for characterization of cancer according to its biological aggressiveness (WP7).  The Candiolo Cancer Institute’s contribution to the ProCAncer-I project includes the uploading of 1,500 MRI examinations, including 250 cases with high quality imaging annotations, of biopsy and pathology data after surgery. In addition, Candiolo Cancer Institute is coordinating all the clinical activities of the other 12 data providers of the ProCAncer-I project.